PDB56 COSTS ASSOCIATED WITH INITIATING EMPAGLIFLOZIN VERSUS OTHER ANTIHYPERGLYCEMIC AGENTS IN PATIENTS WITH TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE: A RETROSPECTIVE COHORT STUDY

May 1, 2019, 00:00 AM
10.1016/j.jval.2019.04.605
https://www.valueinhealthjournal.com/article/S1098-3015(19)30797-1/fulltext
Section Title :
Section Order : 10225
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)30797-1&doi=10.1016/j.jval.2019.04.605
HEOR Topics :
Tags :
Regions :